Website:
www.thinkbio.ai
In This Edition
Message From the CEO
At the heart of this year’s World Cancer Day theme, “United by Unique,” is a simple but powerful truth that every cancer journey is deeply personal. Behind every dataset, every biomarker, and every clinical trial is an individual navigating uncertainty, hope, and difficult choices. At ThinkBio.Ai®, our work is driven by this responsibility. We believe that advancing cancer care requires more than generating insights—it requires connecting fragmented biological and clinical knowledge in ways that are meaningful, explainable, and actionable. Whether it is identifying better therapeutic targets, reducing translational risk, or improvingclinical trial access, the goal remains the same: to enable decisions that are more informed and more human-centered.
Cyclin-Dependent Kinases as Key Targets in Cancer Therapy
Sivasankar PuttaIndustry Insights
ThinkBio Sidney™
AI-Driven Oncology Agent for Mechanism-Driven Decisions
ThinkBio Sidney is an advanced oncology AI platform designed to navigate the complexity of cancer biology and drug development. It integrates multimodal data including scientific literature, omics datasets, and clinical evidence into a unified, mechanism-driven framework across the translational continuum. Cancer research is highly fragmented, making it difficult to extract actionable insight. Sidney addresses this by connecting dispersed biomedical and clinical data and applying AI-driven reasoning to uncover meaningful biological relationships. At its core, Sidney utilises biomedical, clinical trial, and patient-level knowledge graphs to deliver mechanism-centric insights into target biology, disease pathways, drug response, and resistance transforming complexity into actionable intelligence. Built on a multi-agent AI architecture, ThinkBio Sidney enables structured reasoning across targets, diseases, and therapeutic strategies, supporting faster, evidence-based decisions from discovery to clinic.DrugSuccess.Ai®
Predict Therapeutic Success Before Clinical Investment
DrugSuccess.Ai® helps biopharma teams evaluate the likelihood of drug success before entering costly clinical stages. It integrates genetics, multi-omics, disease models, preclinical data, and historical trial outcomes into a unified analytical framework. At its core is the Drug Success Score, an explainable metric that quantifies the probability of a therapy progressing from early research to regulatory approval. By combining curated scientific evidence with knowledge graph–based mapping of targets, pathways, and diseases, the platform provides visibility into translational risk. DrugSuccess.Ai® enables earlier, evidence-based decisions, improving portfolio prioritization and reducing R&D uncertainty.Resource Corner
Decoding Pancreatic Tumor Architecture with Spatial Transcriptomics
Vidya Baiju Our recent case study demonstrates how a Xenium spatial transcriptomics workflow can elucidate the structural and molecular organization of pancreatic cancer tissue. After quality filtering, the dataset is refined from 190,965 detections to 5,779 reliable cells, allowing identification of acinar, ductal, tumor, immune, and stromal regions. The analysis highlights spatial patterns in gene activity, including pathways like GPCR and renin–angiotensin signalling, and identifies gene modules linked to VSIG4‑driven immune suppression and FOXA1‑related epithelial changes. It also uncovers interactions among tumor, fibroblast, and immune cells, detects ACE2‑rich areas, and maps a clear acinar‑to‑ductal‑to‑tumor progression, providing an integrated picture of tumor organization and development.
Harnessing AI for Targeted Genetic Design – A New Approach from ThinkBio.Ai ®
Vrinda Venu & Amal Krishnan M Synthetic DNA enables the design of sequences absent from natural genomes yet capable of encoding specific biological functions. Generating these sequences with predictable characteristics is crucial for advancing research into complex biological systems—particularly for testing how genomic features like promoters and enhancers influence gene expression, predicting evolutionary trajectories, and generating robust datasets when natural training data is insufficient. At ThinkBio.Ai®, we have achieved major advancements in directed DNA design by leveraging Evo2, a state-of-the-art machine learning model trained on extensive genomic datasets. By integrating Evo2 with our proprietary R-COP tool, we successfully targeted specific sequences to incorporate single nucleotide variants (SNVs) and indels at user-specified or functionally impactful loci. Our research specifically focused on directing pathogenicity within the MLH1 promoter region. By carefully adjusting the "temperature" parameter within the Evo2 model, we were able to bias sequence generation toward both benign and harmful mutations. This approach yielded a remarkable correlation between our synthetically generated events and ClinVar annotated mutations (R^2 = 0.9681). Notably, higher temperature settings demonstrated the model's ability to precisely disrupt functional motifs for key transcription factors, including ZNF417, E2F4, E2F1, and HSF4. These results highlight a new level of precision in genetic modification, opening significant doors for diverse applications in computational modeling and functional genomic studies. Read MoreInside TrialFit.Ai®: How ThinkBio.Ai® Is Simplifying Clinical Trial Matching
1: Why is matching patients to clinical trials still such a challenge?
Clinical trials are essential for advancing medical research, but identifying the right trial for the right patient is often slow and labour-intensive. Physicians and research coordinators must navigate hundreds of active studies, interpret complex eligibility criteria, and manually compare those requirements with patient medical records. For patients with complex diseases or rare conditions, this challenge becomes even greater. Many trials require very specific clinical characteristics, prior treatment history, or biomarker profiles. In busy healthcare environments, clinicians are balancing multiple responsibilities, and even highly motivated physicians may struggle to identify every relevant study. Because of this complexity, many patients who could potentially benefit from clinical trials are never matched to them.
2: How is ThinkBio.Ai® addressing this problem?
ThinkBio.Ai® developed TrialFit.Ai® as a practical, clinician-focused platform designed to simplify the trial discovery process. The platform analyzes structured patient information and compares it with eligibility criteria from active clinical trials. Instead of relying on manual searches across multiple databases, clinicians receive a curated list of trials where a patient is most likely to qualify. By automating much of the data comparison process, TrialFit.Ai® allows healthcare teams to focus on evaluating options and guiding patients through the clinical research journey.
3: How does TrialFit.Ai® perform patient-trial matching?
TrialFit.Ai® evaluates patient profiles against trial inclusion and exclusion criteria using structured clinical data. The system reviews multiple parameters simultaneously, including diagnosis, treatment history, and biomarker information. For every potential trial match, the platform provides a Match Score along with a clear explanation of how the patient aligns with the study’s eligibility requirements. This transparency allows clinicians to understand the reasoning behind each recommendation and quickly assess whether a trial is appropriate.
4: What impact can TrialFit.Ai® have in real clinical practice?
In everyday clinical settings, TrialFit.Ai® significantly reduces the time required to identify suitable clinical trials. Tasks that previously required hours of manual searching can be completed in minutes. For clinicians, this reduces and for patients, it improves access to research opportunities that may provide new therapeutic options.
5: How does the platform maintain human oversight?
TrialFit.Ai® is designed as a decision-support tool, not a replacement for clinical judgment. While the platform provides recommendations based on patient and trial data, the final decision always remains with the clinician. Each suggested match includes a detailed eligibility rationale, allowing healthcare professionals to evaluate the reasoning behind the recommendation. When multiple trials are available, the system can also explain why one option may be more suitable than another.
6: How can TrialFit.Ai® support the future of clinical research?
While TrialFit.Ai® currently focuses on efficient patient-trial matching, it also represents a step toward more intelligent clinical workflows. Future developments could integrate additional datasets to provide even deeper insights for clinicians. The same matching intelligence could also support cohort planning, helping research sites and sponsors understand where eligible patient populations exist and how trial criteria affect feasibility. By making trial matching faster and more transparent, TrialFit.Ai® contributes to improving participation in clinical research and ensuring that patients have better access to emerging therapies.Community Corner
ThinkBio.Ai® at AACR 2026
ThinkBio.Ai® will be attending the AACR Annual Meeting 2026 in San Diego, joining the global oncology research community to explore the latest advances in cancer biology and drug development. At AACR, we will be engaging with biopharma and research leaders on how AI and computable biology can help address key challenges in oncology particularly in understanding complex disease mechanisms, reducing translational risk, and improving clinical trial outcomes. Our focus will be on enabling more informed, data-driven decisions across the development pipeline by making biological and clinical data more interpretable, connected, and actionable.About ThinkBio.Ai ®